Dyno Capsidmap News Today

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric...

TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Dyno Therapeutics Inc. said that they have reach an agreement to develop next-generation adeno-associated virus or AAV vectors for gene

Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration May 11, 2021 Share Biogen will partner with Capsigen to engineer novel adeno-associated virus (AAV) capsids for gene therapies designed to treat CNS and neuromuscular disorders, through a strategic research collaboration that could generate more than $1.3 billion for Capsigen. The companies said they will create and identify novel AAV capsids tailored to meet disease-specific transduction profiles through their collaboration, designed...

Dyno Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company applying artificial intelligence (AI) to gene therapy, raised $100m in Series A financing. The round was led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and Lux Capital. Founding investors Polaris Partners, CRV and KdT Ventures all participated in the round. As part of the Series A financing, Jorge Conde, General Partner at Andreessen H...

MedCity News Andreessen Horowitz leads $100M Series A round in Dyno and its gene therapy tech Dyno Therapeutics’ technology for designing viral vectors that deliver gene therapies has led to partnerships with Novartis, Sarepta Therapeutics, and Roche. With the Series A financing, the startup plans to expand its technology to address more tissue types, and potentially add more partners. Shares0 Improved AAV vector capsid for gene therapy engineered with a new machine-guided approach shows, i...